Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin
- PMID: 1878894
- PMCID: PMC11038680
- DOI: 10.1007/BF01741603
Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin
Abstract
To study the mode of action of intravesical bacillus Calmette-Guérin (BCG) immunotherapy in the prevention and cure of superficial bladder cancer, flow-cytofluorometric analysis of the cellular immunological reaction in the urine of patients was performed. Fresh urine-derived leucocytes were obtained from eight patients before (t0) and 24 h (t24) and 48 h (t48) after repeated intravesical BCG instillations (at least 5 instillations). For two patients urine-derived leucocytes were investigated at the first BCG instillation. The number of leucocytes in the urine was markedly increased 24 h after repeated BCG instillations, indicating a local cellular immunological reaction induced by BCG. The mean number of cells per milliliter of urine at that time was 2.9 x 10(6) +/- 3.6 x 10(6) (n = 8). These leucocytes consisted mainly of granulocytes (75 +/- 11%, n = 8). In addition monocytes/macrophages (4 +/- 2%, n = 8) and T lymphocytes were present (1 +/- 1%, n = 5). The relative increase of monocytes/macrophages in the urine after BCG application tended to be higher compared to the other leucocyte subtypes. As T lymphocytes may play an important role in the BCG-mediated anti-tumour activity, subsets of lymphocytes were further characterized at t0, t24, and t48 after repeated BCG instillations. The lymphocyte population consisted mainly of T cells (86% CD3+, t0). Most of the T cells were CD4+ (helper/inducer) and were significantly decreased at 48 h (62 +/- 9% at t0 vs 49 +/- 6% at t48). Lymphocytes partly expressed HLA-DR antigens (44%, t0). The percentage of lymphocytes with interleukin-2 (IL-2) receptors (CD25+) was significantly increased at 24 h and 48 h, compared to pre-instillation values (19 +/- 11% and 10 +/- 4% vs 3 +/- 3% respectively). Natural killer cells (CD16+ and/or CD56+) and B cells (CD19+) were less numerous (10% and 19% at t0 respectively). After the first BCG instillation the increase in the number of leucocytes in urine seemed to be less compared to the numbers after repeated BCG instillations. Lymphocytes could not be detected in the urine collected before or after the first BCG instillation. In conclusion, we demonstrated the presence of considerable numbers of leucocytes in the urine 24 h after repeated BCG instillations, i.e. shortly after immunological activation. The antigen expression of the lymphocytes suggested that they may represent the lymphocytes in the bladder wall. Expression of HLA-DR and IL-2 receptors on lymphocytes indicated activation of T cells by the intravesical BCG treatment.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.Cancer Immunol Immunother. 1992;34(5):306-12. doi: 10.1007/BF01741551. Cancer Immunol Immunother. 1992. PMID: 1540977 Free PMC article.
-
Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.Urol Res. 1991;19(1):45-50. doi: 10.1007/BF00294021. Urol Res. 1991. PMID: 2028562
-
Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin.In Vivo. 1991 Nov-Dec;5(6):671-7. In Vivo. 1991. PMID: 1810454
-
Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.Surg Annu. 1990;22:363-78. Surg Annu. 1990. PMID: 2408170 Review. No abstract available.
-
Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review.Urol Res. 1998;26(3):155-9. doi: 10.1007/s002400050039. Urol Res. 1998. PMID: 9694595 Review.
Cited by
-
CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients.Front Immunol. 2022 Sep 15;13:970931. doi: 10.3389/fimmu.2022.970931. eCollection 2022. Front Immunol. 2022. PMID: 36189320 Free PMC article.
-
Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients.Oncoimmunology. 2012 Aug 1;1(5):694-698. doi: 10.4161/onci.20526. Oncoimmunology. 2012. PMID: 22934261 Free PMC article.
-
Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.Cancer Immunol Immunother. 1992;34(5):306-12. doi: 10.1007/BF01741551. Cancer Immunol Immunother. 1992. PMID: 1540977 Free PMC article.
-
Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.Vaccine. 2021 Dec 8;39(50):7332-7340. doi: 10.1016/j.vaccine.2021.09.053. Epub 2021 Oct 7. Vaccine. 2021. PMID: 34627626 Free PMC article. Review.
-
The mechanism of action of BCG therapy for bladder cancer--a current perspective.Nat Rev Urol. 2014 Mar;11(3):153-62. doi: 10.1038/nrurol.2014.15. Epub 2014 Feb 4. Nat Rev Urol. 2014. PMID: 24492433 Review.
References
-
- Adolphs HD, Schwabe HW, Helpap B, Volz C. Cytomorphological and histological studies on the urothelium during and after chemoimmune prophylaxis. Urol Res. 1984;12:129. - PubMed
-
- Böhle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD. Detection of urinary TNF, IL-1, and IL-2 after local BCG immunotherapy for bladder carcinoma. Cytokine. 1990;2:175. - PubMed
-
- Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local BCG therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol. 1990;144:53. - PubMed
-
- De Boer EC, De Jong WH, Van Der Meijden APM, Steerenberg PA, Witjes JA, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer: a flow cytofluorometric analysis. Urol Res. 1991;1:45. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials